TAOâ¯Synergies Inc. (TAOX)
$3.68-2.13%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $12M
- Beta
- 1.50
- P/E (TTM)
- -0.92
- Short % float
- 21.70%
- Days to cover
- 2.1
- SI change
- +50.2%
- 1W
- -19.30%
- 1M
- -5.64%
- vs SPY 1W
- -19.16%
- vs SPY 1M
- -8.15%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 11
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-48.7%
REV YoY-
ROE-81.2%
EPS YoY-
ROA-78.9%
GROSS100
OP-1085
NET-2155
[VALUATION]
P/E TTM-0.92
P/E FWD-
SECTOR PE48.16
INDUSTRY PE45.05
P/B1.59
P/FCF-
EV/EBITDA-3.00
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO19.99
ND/EBITDA-
BETA1.50
Company news
FAQ
- What is LOPJLB’s current signal on TAOX?
- LOPJLB’s latest quantitative signal on TAOâ¯Synergies Inc. (TAOX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TAOX in?
- TAOâ¯Synergies Inc. (TAOX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does TAOâ¯Synergies Inc. (TAOX) do?
- TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on …